Cart is empty The development of various hypoxia-activated prodrugs (HAPs) has made considerable advances in the last few decades; however, cancer therapy using HAPs is still hindered by problems such as poor therapeutic outcomes due to difficulty in reaching the hypoxic region and metastasis resulting from hypoxia.
Leave A Comment